Capricor Therapeutics (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.
CAPR’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. The HOPE-Duchenne trial was funded in part by the California Institute for Regenerative Medicine.
CAPR is one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
The company was founded in 2005 and is headquartered in Beverly Hills, California.
June 9, 2018
RegMed Investors’ (RMi) closing bell: after the storm, there was a neutral calm upon the sector
June 7, 2018
RegMed Investors’ (RMi) closing bell: another I told you so
June 6, 2018
RegMed Investors’ (RMi) closing bell: feeling the gain yet, a danger zone looms
June 5, 2018
RegMed Investors’ (RMi) closing bell: session stays alive and up
June 4, 2018
RegMed Investors’ (RMi) closing bell: who opened up, where’s the mid-day and I don’t give a damn unless we close up
June 1, 2018
RegMed Investors’ (RMi) closing bell: a good day
May 31, 2018
RegMed Investors’ (RMi) closing bell: the upside softened
May 30, 2018
RegMed Investors’ (RMi) closing bell: comeback
May 29, 2018
RegMed Investors’ (RMi) closing bell: weakness or a panic move?
May 25, 2018
RegMed Investors’ (RMi) closing bell: spritz, slips and a fritz
35 companies, 1 interpreter!
Insight, foresight and recommendation
Capricor (CAPR) --January started out at $1.57 with a high of $1.70 beginning February at $1.83. a high of $2.00 on 2/15 dropping to $1.85 on 2/16 … CAPR desperately NEEDS to re-finance, be ready for depreciation and dilution -
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors